Search

Displaying results 4191 - 4200 of 5262 in total
  1. Drug

    PLT012

    go.drugbank.com/drugs/DB23610
    Investigational

    PLT012 is a humanized anti-CD36 antibody developed by Pilatus Biosciences for treating liver cancer and intrahepatic bile duct cancer.

  2. Drug

    Metyrapone

    go.drugbank.com/drugs/DB01011
    ApprovedInvestigational

    An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

  3. Drug

    Phosphorus P-32

    go.drugbank.com/drugs/DB14551
    Investigational

    Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular

  4. Drug

    Tioguanine

    go.drugbank.com/drugs/DB00352
    ApprovedInvestigational

    An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

  5. Drug

    Edrophonium

    go.drugbank.com/drugs/DB01010
    Approved

    A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.

    Synonyms: 3-hydroxy-N,N-dimethyl-N-ethylanilinium, N-ethyl-3-hydroxy-N,N-dimethylanilinium
  6. Drug

    Pipecuronium

    go.drugbank.com/drugs/DB01338
    ApprovedInvestigationalWithdrawn

    Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.

  7. Drug

    Hydracarbazine

    go.drugbank.com/drugs/DB09243
    Experimental

    Hydracarbazine is a pyridazine that has found use as an antihypertensive agent It was once marketed in France under the tradename Normatensyl.

  8. Drug

    Epothilone D

    go.drugbank.com/drugs/DB01873
    Investigational

  9. Drug

    Gantacurium

    go.drugbank.com/drugs/DB05710
    Investigational

    It is being developed by Avera Pharmaceuticals.

  10. Drug

    DLO6002

    go.drugbank.com/drugs/DB05179
    Experimental

    DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.